Seracare Life Sciences Inc(SRLS)- NASDAQ
SRLS is defunct.
  • Feb. 13, 2012, 9:18 AM

    Shares of SeraCare Life Sciences (SRLS) soar 9.5% in premarket action after Linden Capital Partners agrees to buy the firm, but still sit $0.42 off the agreed upon $4 per share deal price.

    | Feb. 13, 2012, 9:18 AM
  • Feb. 13, 2012, 8:31 AM

    SeraCare Life Sciences (SRLS) agrees to be acquired for $80.8M by PE firm Linden Capital Partners. The $4/share deal reflects a premium of 19% to Friday's closing price. SRLS, which supplies diagnostic control products for HIV, plasma-derived reagents and contract research services, had said last year it was exploring strategic alternatives.

    | Feb. 13, 2012, 8:31 AM
  • Aug. 1, 2011, 8:52 AM

    SeraCare Life Sciences (SRLS) says it will explore and evaluate potential strategic alternatives to enhance shareholder value, including a sale or other transaction, but there is no set timetable for making a decision. SRLS +3.3% premarket. (PR)

    | Aug. 1, 2011, 8:52 AM
  • May 3, 2011, 9:46 AM
    Seracare Life Sciences (SRLS +3%) wins a $17.6M contract to maintain the National Institutes of Health's Specimen Repository. SRLS's 2010 revenue was $50.4M.
    | May 3, 2011, 9:46 AM
Company Description
Currently, there's no company description for SRLS.
Sector: Healthcare
Industry: Drugs - Generic
Country: United States